Business Description
Marinus Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US56854Q2003
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.04 | |||||
Equity-to-Asset | 0.1 | |||||
Debt-to-Equity | 4.4 | |||||
Debt-to-EBITDA | -0.59 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -5.76 | |||||
Beneish M-Score | -3.53 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 109.2 | |||||
3-Year EBITDA Growth Rate | 1.7 | |||||
3-Year EPS without NRI Growth Rate | 2.1 | |||||
3-Year FCF Growth Rate | 0.5 | |||||
3-Year Book Growth Rate | -56.1 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.07 | |||||
Quick Ratio | 4.01 | |||||
Cash Ratio | 3.7 | |||||
Days Inventory | 299.59 | |||||
Days Sales Outstanding | 73.86 | |||||
Days Payable | 674.06 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.3 | |||||
Shareholder Yield % | -2.28 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 93.76 | |||||
Operating Margin % | -424.3 | |||||
Net Margin % | -456.31 | |||||
FCF Margin % | -380.78 | |||||
ROE % | -214.43 | |||||
ROA % | -66.75 | |||||
ROIC % | -993.05 | |||||
ROC (Joel Greenblatt) % | -2969.61 | |||||
ROCE % | -68.81 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2.45 | |||||
PB Ratio | 4.63 | |||||
Price-to-Tangible-Book | 4.59 | |||||
EV-to-EBIT | -0.01 | |||||
EV-to-EBITDA | -0.01 | |||||
EV-to-Revenue | 0.05 | |||||
EV-to-FCF | -0.01 | |||||
Price-to-Net-Current-Asset-Value | 7.09 | |||||
Earnings Yield (Greenblatt) % | -10000 | |||||
FCF Yield % | -151.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Marinus Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 30.989 | ||
EPS (TTM) ($) | -2.63 | ||
Beta | -0.1 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR ($) | 0 | ||
20-Day SMA ($) | 12.343 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 12.343 - 12.343 | ||
Shares Outstanding (Mil) | 54.93 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Marinus Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Marinus Pharmaceuticals Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Marinus Pharmaceuticals Inc Frequently Asked Questions
What is Marinus Pharmaceuticals Inc(LTS:0JYL)'s stock price today?
When is next earnings date of Marinus Pharmaceuticals Inc(LTS:0JYL)?
Does Marinus Pharmaceuticals Inc(LTS:0JYL) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |